Chinese Academy of Sciences

Spreadtrum Communications (shanghai) Co., Ltd.

Semiconductor Manufacturing International (shanghai) Corporation

Semiconductor Manufacturing International (beijing) Corporation

Shanghai Puyi Chemical Co., Ltd.

Tsinghua University

Capitalbio Corporation

Shanghai Theorion Pharmaceutical Co., Ltd.

Xin Xie

Fajun Nan

Jing Li

Hong Tao Liu

Hualiang Jiang

Kaixian Chen

Yangming Zhang

Ying Chen

Yu Chen Zhou

Jing Cheng

Jia Tao Li

Zeng Li

Yubo Zhou

Mingbo Su

Depu Chen

Haifeng Sun

Weiyang Fei

Jian Li

Jian Ding

Qing Shan Zhang

Hui Calvin Yang

Fei Zhao

Fei Chen

Na Li

Siwei Wang

Guochu Chen

Hui Yang

Linghua Meng

Liumeng Yang

Ping Jiang

Yongtang Zheng

Caihong Zhou

Mingwei Wang

Qing Liu

Xuechu Zhen

Hong Liu

Yu Zhou

Xu Zhang

Panfeng Peng

Chaojun Gong

Haonan Zhang

Liyuan Zhu

Ronghua Luo

Xueli Lv

Jia Li

Chenlu Zhang

Shimeng Guo

Linhai Chen

Guangxing Wang

Hui Chai

Beili Wu

Ya Zhu

Yufeng Xiao

Shixian Wang

Cen Xie

Yameng Liu

Disclosed are a pentacyclic triterpene compound as shown in general formula (I) and a preparation method therefor. The compound has an effective antagonistic effect on FXR receptors. 

Pentacyclic triterpene compound and preparation method therefor, and pharmaceutical composition and use thereof

The present invention relates to a GPR84 receptor antagonist and use thereof. The GPR84 receptor antagonist of the present invention has a structure as represented by formula (I), the definitions of R1, R2, R3, R4, L, L, L, L, L, L, Y, Z, and rings A, B, C, and D are as described in the description and claims. The GPR84 receptor antagonist of the present invention can competitively inhibit the activation of the receptor caused by an agonist of GPR84, and can be used in the preparation of a medicament for treating related diseases caused by high expression or high excitability of GPR84 receptor, the diseases including multiple sclerosis, inflammatory bowel disease, arthritis and the like. 

GPR84 receptor antagonist and use thereof

A semiconductor structure and a method for fabricating the semiconductor structure are provided. The method includes providing a plurality of dummy gates on a substrate, a capping layer on each dummy gate, and a dielectric layer over the substrate, wherein the dielectric layer has a top surface above each dummy gate. The method also includes performing a first ion implantation process on the dielectric layer to form a first stop layer in the dielectric layer. A top surface of the first stop layer is above or coplanar with a top surface of each dummy gate. Further, the method includes performing a first planarization process on the capping layer and the dielectric layer to expose the top surface of each dummy gate. A removal rate of the first stop layer is smaller than a removal rate of the dielectric layer when performing the first planarization process.

Semiconductor structure and fabrication method thereof

Provided are 1-(3-aminopropyl) substituted cyclic amine compounds as represented by frmula (I), pharmaceutically acceptable salts, enantiomers, diastereoisomers, racemates and mixtures thereof, and a method of synthesizing said 1-(3-aminopropyl) substituted cyclic amine compounds by using aromatic heterocyclic formaldehyde as raw material. Said compounds can be used as CCR 5 antagonist for the treatment of HIV infection. 

1-(3-aminopropyl) substituted cyclic amine compounds, preparation method therefor, and pharmaceutical compositions and uses thereof

Method and apparatus for controlling a physical layer protocol data unit (PPDU) transmission rate of a physical layer in a first terminal are provided. The method includes: obtaining a media access control protocol data unit (MPDU) retransmission frequency of the first terminal in a first period, where the first terminal is a station or an access point in a wireless network; if the MPDU retransmission frequency is less than a frequency threshold, promoting the PPDU transmission rate in a second period; and else, suppressing the PPDU transmission rate in the second period, where the second period is following and adjacent to the first period along a time axis. The PPDU transmission rate may be adjusted adaptively according to a channel's practical transmission state, the physical layer rate may be prevented from decreasing continuously in noisy channel environment, and a throughput rate may be improved in real time.

Method and apparatus for controlling transmission rate of physical layer

Method and apparatus for controlling length of aggregation frames in a wireless network is provided. The method includes: obtaining a noisy level of a channel based on the number of first data received by a first terminal in a first period, the first terminal being a STA or AP in the wireless network, and the first data include aggregation frames or non-aggregation frames; and determining length of an aggregation frame to be transmitted by the first terminal in a second period based on the noisy level, where the second period is following and adjacent to the first period along a time axis. The first terminal may detect the noisy level and select the length of the aggregation frame based on the noisy level. Thus, inter-frame collision and interference in the channel may be reduced, channel resources may be well utilized, and a throughput rate may be improved in real time.

Method and apparatus for controlling length of aggregation frame in wireless network

Use of hexahydro-dibenzo[a,g]quinolizine compounds as shown in formula(I) in preparing a medicine for treating and/or preventing benign prostate hyperplasia diseases. 

Pharmaceutical use of hexahydro-dibenzo[a,g]quinolizine compounds

Method and apparatus for controlling startup of RTS/CTS mechanism is provided. The method includes: obtaining a noisy level of a channel based on the number of first data received by a first terminal in a first period, where the first terminal is a STA or an AP in a wireless network, and the first data include aggregation frames or non-aggregation frames; and if the noisy level is greater than or equal to a noisy level threshold, controlling the first terminal to start up the RTS/CTS mechanism when data is transmitted in a second period which is following and adjacent to the first period along a time axis. The noisy level of the channel may be obtained in real time, and the RTS/CTS mechanism may be controlled to be started up reasonably in real time, so that channel resources is utilized sufficiently, and a throughput rate is improved.

Method and apparatus for controlling startup of request to send/clear to send mechanism

Method and apparatus for controlling CCA threshold of a wireless communication channel is provided. The method includes: obtaining a noisy level of the channel based on the number of first data received by a first terminal in a first period, the first terminal being a STA or AP in a wireless network, and the first data include aggregation frames or non-aggregation frames; and adjusting the CCA threshold the first terminal uses in data transmission in a second period based on the noisy level. The first terminal may adaptively detect the noisy level of the channel, and the CCA threshold may be selected reasonably based on the noisy level, which enables the first terminal to obtain an opportunity of accessing the channel in time when it needs to send data, enhance the first terminal's competition ability of occupying channels, and improve a throughput rate.

Method and apparatus for controlling clear channel assessment threshold

The present invention relates to a thiazole-based compound, a preparation method therefor, and a use thereof. More specifically, the present invention relates to a 2,2'-bis-thiazole-based compound, a preparation method therefor, and a use of 2,2&#x2032;-bis-thiazole-based compound a histone deacetylase inhibitor in the preparation of an antitumor medicament, a medicament for treating autoimmune diseases, a medicament for treating type II diabetes mellitus and complication thereof, or a medicament for treating neurodegenerative diseases. 

2,2'-tandem dithiazole compound, preparation method therefor, and use thereof

The present invention relates to a novel hexahydrodibenzo[a,g]quinoline compound represented by general formula (I) and its derivatives, enantiomer, diastereoisomer, raceme and mixtures thereof, as well as pharmaceutically acceptable salts thereof. The present invention further relates to a method for preparing the compound, and the compound has good prevention and treatment effect on neurological diseases, especially diseases associated with dopamine receptor and 5-hydroxytryptamine receptor. The bioactivity experiment demonstrates that, the compound is expected to be developed into a novel and potent chemical entity for treating diseases associated with dopamine receptor and 5-hydroxytryptamine receptor, especially schizophrenia, Parkinson's disease, drug addiction, migraine and so on. 

Hexahydrodibenzo[a,g]quinolizine compound, preparation method thereof, pharmaceutical composition and use thereof

The present invention relates to thiazole compounds of formula I, the method for preparation and use thereof. More specifically, the present invention relates to novel derivatives of natural product largazole, the method for preparing them and their uses for treatments against tumor and multiple sclerosis as inhibitors of histone deacetylase. 

Thiazole compounds, methods for preparation and use thereof

The present invention provides a substituted cyclic compound of the following general formula I or II: its preparation process and its use as a glucagon-like peptide-1 receptor regulator for preventing or treating metabolic disorders including, but not limited to, diabetes, insulin resistance and obesity, etc.

Substituted cyclic compound, its preparation process and its medical use

Growing community of inventors

Shanghai, China

Xin Xie